Molecular Templates — Investor Presentation (January 2021)
25 slides from Molecular Templates's investor presentation, Jan 7, 2021
Slide 1: Molecular Templates Corporate Presentation January 2021
Exhibit 99.1 MOLECULAR TEMPLATES Corporate Presentation I January 2021 (NASDAQ: MTEM) Exhibit 99.1 MOLECULAR TEMPLATES Corporate Presentation I January 2021 (NASDAQ: MTEM)
Slide 2: Forward-Looking Statements
Forward-Looking Statements Except for statements of historical fact, the statements in this presentation are forward-looking statements, including, but not limited to, statements regarding the future development of our proprietary Engineered Toxin Body (ETB) technology; statements relating to the po
Slide 3: MTEM: Developing Novel Therapeutics With a Unique Platform
MTEM: Developing Novel Therapeutics With a Unique Platform Unique MOA Global Partners Engineered Toxin Bodies (ETBs) have the specificity of an Takeda: CD38 co-development, multi-target collaboration, equity antibody, can induce their own internalization, and act through a investment. Vertex: Multi-
Slide 4: ETBs: Novel Mechanisms of Action in Oncology
ETBs: Novel Mechanisms of Action in Oncology ETBs use an antibody domain for targeting genetically fused to a Engineered Toxin Bodies de-immunized SLTA − ETBs can be made to bind any extracellular target st rd nd 1 Gen 3 Gen 2 Gen − ETBs retain the SLTA-mediated: Engineered Engineered SLTA SLTA • In
Slide 5: MT-3724 1st-Gen ETB Targeting CD20 for Lymphomas
MT-3724 st 1 -Gen ETB Targeting CD20 for LymphomasMT-3724 st 1 -Gen ETB Targeting CD20 for Lymphomas
Slide 6: MT-3724: 1st-Gen CD20-Targeted ETB
st MT-3724: 1 -Gen CD20-Targeted ETB C D 2 0 TA R G E T E D Single-chain variable fragment (scFv) MT-3724 with specificity to CD20 O T H E R P R O P E R T I E S Fusion protein; no linker chemistry. Short serum half-life; irreversible intra-cellular effects. CD20 binding scFv F O R C E D TA R G E T I
Slide 7: MT-3724: Activity Demonstrated in DLBCL
MT-3724: Activity Demonstrated in DLBCL Phase 1/1b study conducted in heavily pretreated B-cell lymphoma patients • Median age of 65 • Median of 4 prior NHL therapies; median of 2 prior anti-CD20 Mabs Patients evaluable for efficacy in phase I (n=25) DLBCL or Mixed DLBCL/FL (n=19) Deep and prolonged
Slide 8: MT-3724: Update on Partial Clinical Hold
MT-3724: Update on Partial Clinical Hold ● One subject death occurred on 20-Oct-2020 in the MT-3724 monotherapy study due to grade 5 capillary leak syndrome (CLS) − Subject was a seventh line DLBCL patient (ex-US site) who had rapidly progressed through three lines of therapy (including a first- gen
Slide 9: 2nd-Generation ETBs Increased Potency; Better Safety; Reduced Aggregation
2nd-Generation ETBs Increased Potency; Better Safety; Reduced Aggregation2nd-Generation ETBs Increased Potency; Better Safety; Reduced Aggregation
Slide 10: 2nd-Gen ETBs Designed to Have Improved Potency and Reduced Toxicity
nd 2 -gen ETBs Designed to Have Improved Potency and Reduced Toxicity First-gen ETB Next-gen ETBs Wildtype SLTA payload Proprietary De-immunized SLTA payload NHP Tox: HNSTD > 500 ug/kg NHP Tox: HNSTD < 150 ug/kg Treatment- experienced Therapeutic Index Therapeutic Index Treatment- 5 In-vitro potency
Slide 11: 2nd-Gen ETBs Designed to Have Reduced Propensity for Aggregation
nd 2 -gen ETBs Designed to Have Reduced Propensity for Aggregation st MT-3724 (1 -Gen ETB) 2nd-Gen ETBs st- nd 1 gen ETB scaffold design exhibits propensity to form higher order 2 -Gen ETB scaffold designs prevents the creation of multiple species and aggregates via covalent and non-covalent interac
Slide 12: Purity (SE-UPLC): 1st-gen ETB vs 2nd-gen ETB
st nd Purity (SE-UPLC): 1 -gen ETB (MT-3724) vs 2 -gen ETB (MT-5111) st MT-3724 (1 gen) scaffold exhibits propensity to form higher 2nd-gen scaffold prevents the creation of multiple order aggregates via covalent and non-covalent interactions species and covalent aggregation nd st MT-3724 (1 gen ETB
Slide 13: 2nd-Generation ETBs MT-5111 / HER2
2nd-Generation ETBs MT-5111 / HER22nd-Generation ETBs MT-5111 / HER2
Slide 14: MT-5111: A 2nd-Generation HER2-Targeted ETB
nd MT-5111: A 2 -Generation HER-Targeted ETB H E R 2 TA R G E T E D MT-5111: Single-chain variable fragment (scFv) with 2nd-Generation ETB specificity to HER2. Binds a distinct epitope from trastuzumab/pertuzumab N O V E L E N Z Y M AT I C P AY L O A D Primary mechanism of cell-kill - enzymatic ribo
Slide 15: MT-5111: Clinical Development
MT-5111: Clinical Development When MTD reached or rec. Ph. 2 dose determined 1H21 Continued Dose Escalation Expansion in HER2+ non-MBC tumor types Cohorts of 10.0 mcg/kg and above Gastric and other HER2+ tumors in HER2+ non-MBC pts Dose Escalation Cohorts of 0.5, 1.0, 2.0, 3.0, 4.5, and 6.75 mcg/kg
Slide 16: 2nd-Generation ETBs TAK-169 / CD38
2nd-Generation ETBs TAK-169 / CD382nd-Generation ETBs TAK-169 / CD38
Slide 17: TAK-169: A 2nd-Generation CD38-Targeted ETB
nd TAK-169: A 2 -Generation CD38-Targeted ETB C D 3 8 TA R G E T E D TAK-169: Single-chain variable fragment (scFv) with 2nd-Generation ETB specificity to CD38. Binds in the presence of daratumumab N O V E L E N Z Y M AT I C P AY L O A D Primary mechanism of cell-kill - enzymatic ribosome destructio
Slide 18: TAK-169: 2nd-Gen ETB Targeting CD38
nd TAK-169: 2 -Gen ETB Targeting CD38 • CD38 is a poorly-internalizing receptor central to disease CD38-targeting Agents in multiple myeloma Mab: Engineered Toxin Body: • TAK-169 efficiently internalizes and destroys low- or Darzalex TAK-169 high-expressing CD38 • TAK-169 activity is retained in the
Slide 19: 3rd-Gen ETBs / Novel Approach to IO
3rd-Gen ETBs / Novel Approach to IO 2nd-Gen Scaffold + antigen seeding3rd-Gen ETBs / Novel Approach to IO 2nd-Gen Scaffold + antigen seeding
Slide 20: MT-6402: PD-L1 Targeting 3rd-gen ETB
rd MT-6402: PD-L1 Targeting 3 -gen ETB Direct cell-kill of PD-L1+ tumor and immune cells and alteration of the tumor CMV pp65 peptide antigen immunophenotype scFv targeting PD-L1 • ETBs localize to ER/cytosol to “seed” tumors with foreign non-self antigens De-immunized SLTA • Antigen cleaved intrace
Slide 21: MT-6402: Potent Activity Against PD-L1+ Tumor Cells
MT-6402: Potent Activity Against PD-L1+ Tumor Cells Potent effect on PD-L1+ tumor cells: Direct Cell-kill against PD-L1+ tumors through two diverse MOAs • Unprecedented alteration of tumor immunophenotype • Ribosomal destruction is independent of tumor microenvironment • Strong evidence that CMV-spe
Slide 22: MT-6402: Potent Activity Against PD-L1+ Immune Cells in the TME
MT-6402: Potent Activity Against PD-L1+ Immune Cells in the TME Potent effect on PD-L1+ immune cells in NHP model PD effects observed in NHP model with MT-6402 have not been seen with checkpoint antibodies A D D1 D8 D15 D22 MT-6402 depletion of Immune cells and Lymphocyte activation is associated wi
Slide 23: ETBs and IO: PD-L1 ETB Moving to Clinic; New IO Targets
ETBs and IO: PD-L1 ETB Moving to Clinic; New IO Targets in the Works Exploration of additional IO targets where ETB Potent effect on PD-L1+ tumor cells and approach may provide substantial differentiation immune cells CTLA4 lead development work underway; IND Direct cell-kill on tumor cells through
Slide 24: Engineered Toxin Bodies: A Robust Pipeline with Clinical Data in 2021
Engineered Toxin Bodies A Robust Pipeline with Clinical Data in 2021Engineered Toxin Bodies A Robust Pipeline with Clinical Data in 2021
Slide 25: Robust Clinical Pipeline Driving Value of Drug Candidates and Platform
Robust Clinical Pipeline Driving Value of Drug Candidates and Platform Program (Target) Indication/Phase 1Q21 2Q21 3Q21 4Q21 Potential resolution of Decision regarding MT-3724 Ph. 2 studies MT-3724 NHL/Ph. 2 (CD20) partial clinical hold vs. acceleration of next-gen CD20 ETB Phase 1 dose escalation d
Molecular Templates — Investor Presentation (January 2021) on 6ix